Lombard Odier Asset Management (USA)’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Lombard Odier Asset Management (USA)’s Portfolio EIDX Stock Details EIDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-15,500	Closed	-$2.04M	–	437
2020 Q4	$2.04M	Buy	+15,500	New	+$1.37M	0.1%	165

Lombard Odier Asset Management (USA)'s EIDX Position: Q1 2021 in Review

Lombard Odier Asset Management (USA) sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2021, closing a stake of 15,500 shares — an estimated $2.04M sold.

Lombard Odier Asset Management (USA) first reported a position in EIDX in Q4 2020 and held it in 1 quarter. The position peaked at $2.04M in Q4 2020. 0 funds tracked by Wall St. Rank hold EIDX as of Q1 2021.

Lombard Odier Asset Management (USA) reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
Lombard Odier Asset Management (USA) sold 15,500 Eidos Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $2.04M.
Lombard Odier Asset Management (USA) first reported a position in Eidos Therapeutics, Inc. Common Stock in Q4 2020 and held it in 1 quarter.
Lombard Odier Asset Management (USA)'s Eidos Therapeutics, Inc. Common Stock position peaked at $2.04M in Q4 2020.
0 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Lombard Odier Asset Management (USA)'s 13F filing for Q1 2021, filed 17 May 2021.